1.
Cancer Discov
; 13(12): 2515-2524, 2023 12 12.
Artículo
en Inglés
| MEDLINE
| ID: mdl-38084090
RESUMEN
SUMMARY: Cancer drug development remained robust in 2023. Highlights of U.S. drug approvals this year include new immunotherapies and targeted drug development in adult and pediatric patients as well as patients with rare diseases.